This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignees: Pharma Foods International Co., Ltd., Public University Corporation Nagoya City University, Yokohama City University. Active years: 2010-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 10 
2 out of 29 
2 out of 57 
Years Active: 2010-2025
Title: Inventor Spotlight: Satoshi Kanazawa
Introduction: Satoshi Kanazawa is a distinguished inventor based in Nagoya, Japan. With two notable patents to his name, Kanazawa has made impactful contributions, particularly in the field of biomedical research. His innovative spirit has propelled advancements in treatments for rheumatoid arthritis.
Latest Patents: Kanazawa's latest patents include groundbreaking research on anti-PAD4 antibodies. These antibodies exhibit excellent properties for treating rheumatoid arthritis (RA) by specifically binding to an epitope at positions 345, 347, and 348 of PAD4. The anti-PAD4 antibodies have the capability to inhibit the citrullination activity of PAD4 and display a KD (M) of 9.0×10 or less. In an innovative approach, these antibodies can be used in combination with TNFα inhibitors for enhanced therapeutic efficacy.
Additionally, Kanazawa has developed a patent for a transgenic nonhuman mammal that effectively represents the pathological conditions of human rheumatoid arthritis. This transgenic model is generated by incorporating foreign DNA regulated by a type II collagen promoter, providing significant insights into the disease mechanisms.
Career Highlights: Kanazawa's professional journey includes valuable contributions at the Nagoya Industrial Science Research Institute and the Public University Corporation Yokohama City University. His work in these institutions has fostered collaboration among experts and propelled research initiatives in biotechnology.
Collaborations: Throughout his career, Kanazawa has worked closely with notable colleagues such as Takashi Okamoto and Mamoru Sato. Their collaborative efforts have enriched the research landscape and advanced the understanding of complex biomedical issues.
Conclusion: Satoshi Kanazawa stands out as an impactful inventor in the field of biomedical innovation. With his patents aimed at improving treatments for rheumatoid arthritis, he continues to inspire and drive progress within the scientific community. His dedication to research and collaboration reflects not only his expertise but also his commitment to finding solutions for pressing health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile